Publications by authors named "Daniel J Flores"
Article Synopsis
- The study discusses AZD3152, a monoclonal antibody created to neutralize SARS-CoV-2 and enhance effectiveness against new variants that can resist other treatments.
- AZD3152 targets a specific part of the virus's spike protein, blocking its ability to bind to human cells and effectively neutralizes various variants, including Omicron, but struggles against certain XBB subvariants.
- In animal trials, AZD3152 helped protect hamsters from severe symptoms and lung issues, and initial human trials suggest it is safe and may offer long-lasting protection against certain strains of COVID-19.
Article Synopsis
- Despite the success of COVID-19 vaccines, there is still a need for additional prevention and treatment methods for at-risk individuals.
- AZD7442 is a combination of two monoclonal antibodies that target different parts of the SARS-CoV-2 spike protein, effectively neutralizing the virus and preventing its entry into human cells.
- Clinical studies suggest that AZD7442 can provide long-lasting protection, potentially up to 12 months, especially benefiting those at higher risk for severe COVID-19 outcomes.
Cardiac calsequestrin (Casq2) associates with the ryanodine receptor 2 channel in the junctional sarcoplasmic reticulum to regulate Ca2+ release into the cytoplasm. Patients carrying mutations in CASQ2 display low resting heart rates under basal conditions and stress-induced polymorphic ventricular tachycardia (CPVT). In this study, we generate and characterize novel conditional deletion and conditional rescue mouse models to test the influence of developmental programs on the heart rate and CPVT phenotypes.
View Article and Find Full Text PDF